Proactive Investors - Run By Investors For Investors

Circassia Pharmaceuticals study data published in leading medical journal

The ASCENT phase IV study assessed the potential of the company's drug Tudorza to treat moderate-to-very severe chronic obstructive pulmonary disease
tudorza inhaler
The data showed the inhaled powder was effective at combating exacerbations (worsening of the symptoms) of COPD with no increase in major cardiovascular events

Circassia Pharmaceuticals PLC (LON:CIR) said findings from a recent clinical trial of one of its key drugs will appear in a prestigious scientific publication.

The Journal of the American Medical Association will carry the results from the ASCENT phase IV study, which assessed the potential of Tudorza to treat moderate-to-very severe chronic obstructive pulmonary disease (COPD).

The data showed the inhaled powder was effective at combating exacerbations (worsening of the symptoms) of COPD with no increase in major cardiovascular events.

Heart disease often goes hand in hand with COPD and 30% of patients die as a result of related conditions.

The phase IV trial provided what’s called a label extension for Tudorza, which means the drug can be administered to a wider patient group.

Circassia chief executive Steve Harris said: "The publication of these clinical results in the prestigious Journal of the American Medical Association further demonstrates Tudorza's safety and efficacy, particularly in this group of at-risk patients. 

“We are delighted at this recognition of the importance of these data, and of the recent inclusion of this new information in Tudorza's prescribing information."

View full CIR profile View Profile

Circassia Pharmaceuticals Timeline

Related Articles

cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use